Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
177 hedge funds and large institutions have $2.57B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2015 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 25 closing their positions.
319% more call options, than puts
Call options by funds: $96.7M | Put options by funds: $23.1M
164% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 25
126% more capital invested
Capital invested by funds: $1.14B → $2.57B (+$1.43B)
88% more funds holding in top 10
Funds holding in top 10: 8 → 15 (+7)
30% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 43
30% more funds holding
Funds holding: 136 → 177 (+41)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.4M |
| 2 |
LCM
LionEye Capital Management
New York
|
+$34.5M |
| 3 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
+$31.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5M |
| 5 |
JP Morgan Chase
New York
|
+$26.5M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.6M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$43.6M |
| 3 |
BC
Broadfin Capital
New York
|
-$34.2M |
| 4 |
HM
HealthCor Management
New York
|
-$29.3M |
| 5 |
MRM
Michael R. Murphy
|
-$28.2M |
HZNP Hedge Fund Activity: Q1 2015 in Review
177 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2015, worth a combined $2.57B — up 126% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new HZNP positions and 25 closed out — a net gain of 41 holders — while 56 added to existing stakes and 43 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $48.4M. The largest seller was Point72 Asset Management, cutting an estimated $43.6M.
- 177 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2015, up from 136 in Q4 2014.
- Funds reported $2.57B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2015, up 126% quarter-over-quarter.
- 66 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2015 and 25 closed out, a net change of +41 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2015 was Fidelity Investments, an estimated $48.4M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2015 was Point72 Asset Management, an estimated $43.6M sold.
Based on aggregated 13F filings for Q1 2015.